Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been the company’s driving focus for years. Now, with Jakafi approaching ...

Despite the healthy growth, Incyte provided guidance for leading drugs, Jakafi and Opzelura, that were below expectations. Management expects sales of the hematology drug Jakafi to be between $2. ...

Adjusted EPS was $1.43, missing the $1.56 estimate. Jakafi revenue rose 11% to $773.1M, while Opzelura sales jumped 48% to $161.6M. Minjuvi/Monjuvi revenue surged 265% to $32.81M. Our government ...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, ...

The Prime Minister, Justin Trudeau, today issued the following statement on International Women's Day: "Women in Canada have made transformative progress in shaping our country for the better. Today, ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and projections for 2025 sales of key medications fell short of analysts' ...